These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 24019195)

  • 1. Use of prescription antiobesity drugs in the United States.
    Hampp C; Kang EM; Borders-Hemphill V
    Pharmacotherapy; 2013 Dec; 33(12):1299-307. PubMed ID: 24019195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study.
    Viner RM; Hsia Y; Neubert A; Wong IC
    Br J Clin Pharmacol; 2009 Dec; 68(6):844-51. PubMed ID: 20002078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of psychotropic drugs and analgesics among users of antiobesity drugs--a population based study.
    Amundsen MO; Engdahl B; Berg C; Nordeng H
    Pharmacoepidemiol Drug Saf; 2010 Mar; 19(3):273-9. PubMed ID: 20014050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s.
    Thomas CE; Mauer EA; Shukla AP; Rathi S; Aronne LJ
    Obesity (Silver Spring); 2016 Sep; 24(9):1955-61. PubMed ID: 27569120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of Antiobesity Treatment and Weight-Inducing Antihyperglycemic Agents Among Patients With Type 2 Diabetes in the United States.
    Levin A; Kaur N; Mainoo NK; Perez A
    Clin Ther; 2022 Mar; 44(3):e35-e44. PubMed ID: 35105470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National trends in antiobesity medication use.
    Stafford RS; Radley DC
    Arch Intern Med; 2003 May; 163(9):1046-50. PubMed ID: 12742801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Obesity: Pharmacotherapy Trends of Office-Based Visits in the United States From 2011 to 2016.
    Claridy MD; Czepiel KS; Bajaj SS; Stanford FC
    Mayo Clin Proc; 2021 Dec; 96(12):2991-3000. PubMed ID: 34728060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Antiobesity Drugs for Adolescents With Severe Obesity.
    Mital S; Nguyen HV
    JAMA Netw Open; 2023 Oct; 6(10):e2336400. PubMed ID: 37824146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular co-medication among users of antiobesity drugs: a population-based study.
    Amundsen MO; Engdahl B; Berg C; Nordeng H
    Pharm World Sci; 2010 Dec; 32(6):752-8. PubMed ID: 20803315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States.
    Suissa K; Schneeweiss S; Kim DW; Patorno E
    Diabetes Obes Metab; 2021 Jul; 23(7):1542-1551. PubMed ID: 33651454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T
    Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database.
    Gorelik E; Gorelik B; Masarwa R; Perlman A; Hirsh-Raccah B; Matok I
    Int J Obes (Lond); 2020 May; 44(5):1021-1027. PubMed ID: 32152496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorrect use of orlistat and sibutramine in clinical practice.
    Dahlin A; Beermann B
    Eur J Clin Pharmacol; 2007 Feb; 63(2):205-9. PubMed ID: 17205321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How physician obesity specialists use drugs to treat obesity.
    Hendricks EJ; Rothman RB; Greenway FL
    Obesity (Silver Spring); 2009 Sep; 17(9):1730-5. PubMed ID: 19300434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time series analyses of the effect of FDA communications on use of prescription weight loss medications.
    Block JP; Choudhry NK; Carpenter DP; Fischer MA; Brennan TA; Tong AY; Matlin OS; Shrank WH
    Obesity (Silver Spring); 2014 Mar; 22(3):943-9. PubMed ID: 23929685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The limits and challenges of antiobesity pharmacotherapy.
    Gadde KM; Atkins KD
    Expert Opin Pharmacother; 2020 Aug; 21(11):1319-1328. PubMed ID: 32292094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Observational Comparative Effectiveness of Pharmaceutical Treatments for Obesity within the Veterans Health Administration.
    Grabarczyk TR
    Pharmacotherapy; 2018 Jan; 38(1):19-28. PubMed ID: 29044720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twelve-year trend in the use of zolpidem and physicians' non-compliance with recommended duration: a Korean national health insurance database study.
    Jang Y; Song I; Oh IS; Shin JY
    Eur J Clin Pharmacol; 2019 Jan; 75(1):109-117. PubMed ID: 30280207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety assessment of an anti-obesity drug (sibutramine): a retrospective cohort study.
    Tyczynski JE; Oleske DM; Klingman D; Ferrufino CP; Lee WC
    Drug Saf; 2012 Aug; 35(8):629-44. PubMed ID: 22788234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.